Ressources

Normal human immunoglobulins (IG) are used to treat patients with primary and secondary antibody deficiencies to supplement missing or malfunctioning antibodies and prevent occurrence of severe infections.

This report presents the case for expanding the availability of blood plasma for the production of plasma-derived medicinal products for patients in all European countries, by growing local donations of plasma.

In collaboration with industry regulators and stakeholders, PPTA has developed a system that we believe is the best way to present the distribution of core plasma protein therapies in North America.